BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19669601)

  • 41. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
    Zighelboim I; Powell MA; Babb SA; Whelan AJ; Schmidt AP; Clendenning M; Senter L; Thibodeau SN; de la Chapelle A; Goodfellow PJ
    Fam Cancer; 2009; 8(4):501-4. PubMed ID: 19672700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer.
    Bapat BV; Madlensky L; Temple LK; Hiruki T; Redston M; Baron DL; Xia L; Marcus VA; Soravia C; Mitri A; Shen W; Gryfe R; Berk T; Chodirker BN; Cohen Z; Gallinger S
    Hum Genet; 1999 Feb; 104(2):167-76. PubMed ID: 10190329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States.
    Lynch HT; Coronel SM; Okimoto R; Hampel H; Sweet K; Lynch JF; Barrows A; Wijnen J; van der Klift H; Franken P; Wagner A; Fodde R; de la Chapelle A
    JAMA; 2004 Feb; 291(6):718-24. PubMed ID: 14871915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel germline mutation (300-305delAGTTGA) in the human MSH2 gene in hereditary non-polyposis colorectal cancer (HNPCC).
    Glasl S; Papatheodorou L; Baretton G; Jung C; Gross M
    Hum Mutat; 2000 Jul; 16(1):91-2. PubMed ID: 10874318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome.
    Froggatt NJ; Brassett C; Koch DJ; Evans DG; Hodgson SV; Ponder BA; Maher ER
    J Med Genet; 1996 Sep; 33(9):726-30. PubMed ID: 8880570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
    Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
    Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers.
    Zhang J; Lindroos A; Ollila S; Russell A; Marra G; Mueller H; Peltomaki P; Plasilova M; Heinimann K
    Cancer Res; 2006 Jan; 66(2):659-64. PubMed ID: 16423994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of the outcome of genetic testing in HNPCC kindreds using the revised Amsterdam criteria and immunohistochemistry.
    Stormorken AT; Müller W; Lemkemeyer B; Apold J; Wijnen JT; Fodde R; Möslein G; Møller P
    Fam Cancer; 2001; 1(3-4):169-73. PubMed ID: 14574174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
    N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting.
    Ramsoekh D; Wagner A; van Leerdam ME; Dinjens WN; Steyerberg EW; Halley DJ; Kuipers EJ; Dooijes D
    Gut; 2008 Nov; 57(11):1539-44. PubMed ID: 18625694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three novel germline mutations in MLH1 and MSH2 in families with Lynch syndrome living on Jeju island, Korea.
    Kim YM; Choe CG; Cho SK; Jung IH; Chang WY; Cho M
    BMB Rep; 2010 Oct; 43(10):693-7. PubMed ID: 21034533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
    Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
    Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic DNA-based hMSH2 and hMLH1 mutation screening in 32 Eastern United States hereditary nonpolyposis colorectal cancer pedigrees.
    Weber TK; Conlon W; Petrelli NJ; Rodriguez-Bigas M; Keitz B; Pazik J; Farrell C; O'Malley L; Oshalim M; Abdo M; Anderson G; Stoler D; Yandell D
    Cancer Res; 1997 Sep; 57(17):3798-803. PubMed ID: 9288790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
    Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.